ArticleStem cell research & therapy2019
Therapeutic effects of human umbilical cord mesenchymal stem cell-derived microvesicles on premature ovarian insufficiency in mice.
Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Mesenchymal stem cell-derived extracellular vesicles therapy for primary ovarian insufficiency: a systematic review and meta-analysis of pre-clinical studies.Journal of ovarian research · 2024Pooled it
- Stem cell-derived extracellular vesicles in premature ovarian failure: an up-to-date meta-analysis of animal studies.Journal of ovarian research · 2024Pooled it
- Therapeutic prospect on umbilical cord mesenchymal stem cells in animal model with primary ovarian insufficiency: a meta-analysis.Frontiers in medicine · 2023Pooled it
- Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects.Frontiers in immunology · 2022Pooled it
- Nanotechnology in reproductive medicine: from gamete engineering to precision therapeutics.RSC advances · 2026Review
- Article
- Mesenchymal Stem Cell-Derived Exosomes for Ovarian Reserve: A Systematic Review and Network Meta‑Analysis Based on Animal Studies.Stem cell reviews and reports · 2026Review
- Therapeutic Effects of Stromal Stem Cells Derived from Ovarian Tissue in a Cyclophosphamide-Induced Rat Model of Ovarian Failure.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Nanomotor-Driven Extracellular Vesicles With Effective Tissue Penetration for Targeted Therapy of Primary Ovarian Insufficiency.Journal of extracellular vesicles · 2026Article
- MSC-derived microvesicles inhibit the progression of arthritis in a murine model of preclinical rheumatoid arthritis.Frontiers in immunology · 2026Article
- Preventing ovarian aging: from redox-targeted strategies to extracellular vesicle-based therapies.Frontiers in aging · 2026Review
- Current status and future prospects of mesenchymal stem cell-derived exosomes therapy for premature ovarian insufficiency.Journal of ovarian research · 2025Review
- Quercetin-loaded mesenchymal stem cell derived extracellular vesicles enhance ovarian function in a cyclophosphamide induced ovarian damage.Journal of ovarian research · 2025Article
- Mesenchymal stem cells and platelet rich plasma in the treatment of premature ovarian insufficiency: a scoping review.Contraception and reproductive medicine · 2025Review
- Precision medicine in premature ovarian insufficiency: a focus on the precision therapeutic strategies for mesenchymal stem cells.Stem cell research & therapy · 2025Review
- Mitigating chemotherapy-induced granulosa cell damage: role of hUCMSC-EVs in regulating the lncRNA HCP5-miR-20a-5p-YAP1 network.Cell biology and toxicology · 2025Article
- Review
- Network Pharmacology, Molecular Docking, and Experimental Validation on Guiluoshi Anzang Decoction Against Premature Ovarian Insufficiency.Combinatorial chemistry & high throughput screening · 2025Article
- Bridging tradition and innovation: electroacupuncture's impact on premature ovarian insufficiency.Frontiers in endocrinology · 2025Review
- Biological Nanotherapeutics Derived From Human Umbilical Cord Mesenchymal Stem Cells: Mechanisms and Translational Potential in Multisystem Therapies for Regeneration and Oncology.International journal of nanomedicine · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPremature ovarian insufficiency (POI) is one of the leading causes of female infertility, which is caused by an abnormal ovarian reserve. Currently, there is no effective treatment to restore the fertility of POI patients. Recent studies suggested that microvesicles (MVs) released from mesenchymal stem cells (MSCs) exert therapeutic effects in various degenerative diseases. In this study, the effect of human umbilical cord MSC-derived MVs (HUCMSC-MVs) on the restoration of ovarian function in a chemotherapy-induced POI mouse model is investigated.
methodsMVs were obtained from the supernatant of cultured HUCMSCs. The localization of PKH26-labeled HUCMSC-MVs in ovarian tissues was observed by confocal laser scanning microscopy. Histomorphometric analysis was performed to count the number of ovarian follicles and vessels. The ovarian sections were stained with anti-CD34 to evaluate angiogenesis. The levels of estradiol (E2) and follicle-stimulating hormone (FSH) were measured by enzyme-linked immunosorbent serologic assay. The mRNA expression of angiogenesis-related cytokines and the protein expression of AKT in mouse ovaries were measured by quantitative RT-PCR and western blot analysis. The parametric variables were compared by Student's t test and analysis of variance. The non-parametric variables were compared by the Mann-Whitney U test. Categorical variables were compared by χ
resultsPKH26-labeled HUCMSC-MVs were detectable within the ovaries and migrated to the ovarian follicles 24 h after transplantation. The transplantation of HUCMSC-MVs could increase the body weight and number of ovarian follicles (primordial, developing, and preovulatory follicles), induce ovarian angiogenesis, and recover the disturbed estrous cycle of POI mice. The expression levels of total AKT, p-AKT, and angiogenic cytokines (including VEGF, IGF, and angiogenin) in the ovaries of POI mice were markedly upregulated after HUCMSC-MVs transplantation, suggesting that HUCMSC-MVs transplantation might recover ovarian function by inducing angiogenesis via the PI3K/AKT signaling pathway.
conclusionsThis study provides valuable insight into the effects of HUCMSC-MVs on ovarian tissue angiogenesis and on the restoration of ovarian function in POI mice, which may be helpful to develop a treatment strategy for POI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.